Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02898116
Title A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Ludwig Institute for Cancer Research

lung non-small cell carcinoma


Durvalumab + Ensartinib


Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Research Facility New York New York 10016 United States Details
*Shaded cells indicate that there was no data available from for the field